Avalyn Pharma Inc. (NASDAQ:AVLN) Stock Has Average Target Price of $60.00

Shares of Avalyn Pharma Inc. (NASDAQ:AVLN) have been assigned a consensus recommendation of “Moderate Buy” from the seven ratings firms that are currently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation, three have given a buy recommendation and two have given a strong buy recommendation to the company. The average 1-year price target among brokers that have updated their coverage on the stock in the last year is $60.00.

A number of equities research analysts have recently issued reports on AVLN shares. Raymond James Financial initiated coverage on shares of Avalyn Pharma in a research report on Friday. They set an “outperform” rating and a $60.00 price objective for the company. Wall Street Zen cut shares of Avalyn Pharma from a “hold” rating to a “sell” rating in a research report on Sunday, September 20th. Weiss Ratings initiated coverage on Avalyn Pharma in a research report on Thursday, August 13th. They issued a “sell (d+)” rating on the stock. Finally, Morgan Stanley increased their price objective on shares of Avalyn Pharma from $53.00 to $57.00 and gave the company an “overweight” rating in a research report on Thursday, August 13th.

Institutional Investors Weigh In On Avalyn Pharma

Large investors have recently added to or reduced their stakes in the stock. State Street Corp bought a new position in Avalyn Pharma during the 2nd quarter worth about $10,501,000. Braidwell LP purchased a new position in Avalyn Pharma during the 2nd quarter worth $26,382,000. Montanova Capital LLC acquired a new position in shares of Avalyn Pharma during the second quarter valued at about $82,402,000. Finally, Bank of New York Mellon Corp acquired a new position in Avalyn Pharma during the 2nd quarter valued at approximately $1,321,000.

Avalyn Pharma Trading Up 2.6%

AVLN opened at $28.13 on Thursday. Avalyn Pharma has a 12-month low of $24.15 and a 12-month high of $40.17. The company has a market capitalization of $1.25 billion and a P/E ratio of -1.23. The business has a fifty day moving average price of $33.49. The company has a debt-to-equity ratio of 0.04, a quick ratio of 33.12 and a current ratio of 33.12.

Avalyn Pharma (NASDAQ:AVLN) last announced its quarterly earnings data on Wednesday, August 12th. The company reported ($0.98) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.03) by $0.05. On average, analysts predict that Avalyn Pharma will post -3.81 EPS for the current year.

Avalyn Pharma Company Profile

Avalyn Pharma, Inc is a clinical-stage biopharmaceutical company focused on developing inhaled therapies for serious fibrotic lung diseases. The company’s primary focus is pulmonary fibrosis, a group of progressive conditions in which scar tissue builds up in the lungs and impairs breathing.

Avalyn’s lead product candidate is AP01, an inhaled formulation of pirfenidone being developed for the treatment of idiopathic pulmonary fibrosis and other forms of pulmonary fibrosis. By delivering therapy directly to the lungs, Avalyn aims to provide a treatment option that may improve local drug exposure while potentially reducing some of the tolerability challenges associated with oral antifibrotic therapies.

The company’s development programs are centered on advancing inhaled medicines through clinical testing and, if successful, regulatory review.